Plasma nontargeted peptidomics discovers potential biomarkers for major depressive disorder.

In conclusion, the excellent performance of the BLR model in both discovery and validation sets demonstrates the robustness of the four peptide markers panel. It is very valuable for quantification of the absolute content of four peptides and further verification.